Shares of The Spectranetics Corp. (NASDAQ:SPNC) were up 5.6% on Wednesday . The stock traded as high as $21.57 and last traded at $21.57, with a volume of 234,174 shares. The stock had previously closed at $20.43.

Several analysts have recently weighed in on SPNC shares. Canaccord Genuity restated a “buy” rating on shares of The Spectranetics Corp. in a research report on Tuesday, July 12th. Stifel Nicolaus restated a “buy” rating on shares of The Spectranetics Corp. in a research report on Monday, June 20th. Guggenheim started coverage on shares of The Spectranetics Corp. in a research report on Wednesday, June 8th. They set a “buy” rating and a $23.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $21.00 price objective on shares of The Spectranetics Corp. in a research report on Thursday, March 31st. Finally, Zacks Investment Research downgraded shares of The Spectranetics Corp. from a “hold” rating to a “sell” rating in a research report on Saturday, April 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.67.

The stock’s 50-day moving average is $19.36 and its 200 day moving average is $16.23. The stock’s market cap is $917.46 million.

The Spectranetics Corp. (NASDAQ:SPNC) last issued its quarterly earnings data on Thursday, April 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. The business had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.41 million. During the same period last year, the business earned ($0.30) earnings per share. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. Equities analysts anticipate that The Spectranetics Corp. will post ($1.11) earnings per share for the current fiscal year.

Several institutional investors have added to or reduced their stakes in the stock. Morgan Stanley boosted its position in The Spectranetics Corp. by 343.2% in the fourth quarter. Morgan Stanley now owns 74,094 shares of the company’s stock valued at $1,116,000 after buying an additional 57,376 shares during the period. California State Teachers Retirement System boosted its position in The Spectranetics Corp. by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 78,596 shares of the company’s stock valued at $1,184,000 after buying an additional 1,478 shares during the period. Finally, OppenheimerFunds Inc. boosted its position in The Spectranetics Corp. by 2.8% in the fourth quarter. OppenheimerFunds Inc. now owns 835,488 shares of the company’s stock valued at $12,582,000 after buying an additional 22,980 shares during the period.

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.